Journal of Clinical & Experimental OncologyISSN: 2324-9110

Reach Us +1 850 900 2634
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Case Report, J Clin Exp Oncol Vol: 6 Issue: 2

Lack of Response to Vismodegib in a Patient with Advanced Basal Cell Carcinoma: A Case Report

Rodríguez-Cerdeira C1* and Muñoz-Garzón V2
1Department of Dermatology, CHUVI & University of Vigo, Vigo, Spain
2Department Oncology and Radiotherapy, CHUVI, Vigo, Spain
Corresponding author : Carmen Rodriguez Cerdeira
Department of Dermatology, Dermatology Service, Meixoeiro hospital, CHUVI & University of Vigo, Vigo C/Meixoeiro S/N 36200, Vigo, Spain
Tel: 0034986814517/0034600536114
Fax: 004986276416
E-mail: [email protected]
Received: January 06, 2017 Accepted: January 25, 2017 Published: February 02, 2017
Citation: Rodríguez-Cerdeira C, Muñoz-Garzón V (2017) Lack of Response to Vismodegib in a Patient with Advanced Basal Cell Carcinoma: A Case Report. J Clin Exp Oncol 6:2.. doi:10.4172/2324-9110.1000177

Abstract

Purpose: Basal cell carcinoma (BCC), the most common type of skin cancer in humans, rarely progresses to locally advanced or metastatic BCC. The size, extent, and location of the lesion should be carefully considered when selecting a treatment option for patients with BCC.

Methods: Moreover, clinicians should review the potential for significant deformity and anticipated morbidity, when considering radiation therapy and surgery for treatment. Vismodegib, the first approved oral therapy for advanced BCC, is a treatment option that clinicians might consider for patients with BCC lesions that exhibit the clinical characteristics as described above.

Results: In this manuscript, we reviewed the mechanism of action, clinical efficacy, and safety of vismodegib and consider the possible causes for a lack of response to the drug.

Conclusion: The therapeutic response to these tumors may be limited by the challenge of acquired resistance against smoothened antagonists.

Keywords: Basal cell carcinoma (BCC); High-risk BCC; Locally advanced BCC;Metastatic BCC; Hedgehog pathway inhibitors

Track Your Manuscript

Share This Page

Media Partners